Literature DB >> 17944743

IL-12p40-independent induction of protective immunity upon multiple Plasmodium berghei irradiated sporozoite immunizations.

J F Romero1, G H Ibrahim, J Renggli, H Himmelrich, P Graber, G Corradin.   

Abstract

Both IFN-gamma and IL-12 play critical roles in defence against malaria. In a previous study, using Plasmodium yoelii model, C57BL/6 IFN-gamma receptor deficient mice (IFN-gammaR-/-) failed to develop protective immunity after a single immunization with irradiated sporozoites, but were protected after multiple immunizations. In contrast, in another study, BALB/c IFN-gamma gene knockout mice (IFN-gamma-/-) and BALB/c IL-12-deficient mice (IL-12p40-/- and IL-12p35-/-) were unable to mount protective immune response even after multiple immunizations with the same irradiated parasites. To better define the role of IFN-gamma and IL-12p40 in sterile protection, we selected the C57BL/6 model. Wild-type and IL-12p40-/- mice were immunized with a single or multiple doses of P. berghei irradiated sporozoites. While the wild-type mice were able to rapidly produce IFN-gamma and mount a protective immune response after a single immunization with irradiated sporozoites, IL-12p40-/- mice were neither able to produce IFN-gamma nor were protected. However, both strains of mice were able to produce IFN-gamma and were protected after three doses of irradiated sporozoites. Protection was partially and largely mediated by CD4+ T cells and CD8+ T cells, respectively. Thus, IL-12p40 plays an important role in mediating early protection by irradiated sporozoite immunization but is dispensable for protective immunity induced by several immunizations with irradiated sporozoites. Moreover, treatment of hyperimmune IL-12p40-/- mice with rhIL-18 bp-Fc, an inhibitor of IL-18 activity, did not abrogate protection indicating that IL-18 is not required for the effector phase of the immune response; it remains possible, however, that IL-18 may compensate for the lack of IL-12p40 in the induction phase of the immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17944743     DOI: 10.1111/j.1365-3024.2007.00972.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  5 in total

1.  Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites.

Authors:  Alejandro Jordán-Villegas; Anilza Bonelo Perdomo; Judith E Epstein; Jesús López; Alejandro Castellanos; María R Manzano; Miguel A Hernández; Liliana Soto; Fabián Méndez; Thomas L Richie; Stephen L Hoffman; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

2.  Impact of chemoprophylaxis immunisation under halofantrine (CPS-HF) drug cover in Plasmodium yoelii Swiss mice malaria model.

Authors:  Arif Jamal Siddiqui; Jyoti Bhardwaj; Walid Sabri Hamadou; Manish Goyal; Sadaf Jahan; Syed Amir Ashraf; Arshad Jamal; Pankaj Sharma; Manojkumar Sachidanandan; Riadh Badraoui; Mejdi Snoussi; Mohd Adnan
Journal:  Folia Parasitol (Praha)       Date:  2022-02-03       Impact factor: 2.122

3.  Chemoprophylaxis under sporozoites-lumefantrine (CPS-LMF) immunization induce protective immune responses against Plasmodium yoelii sporozoites infection in mice.

Authors:  Arif Jamal Siddiqui; Jyoti Bhardwaj; Walid Sabri Hamadou; Manish Goyal; Syed Amir Ashraf; Sadaf Jahan; Arshad Jamal; Pankaj Sharma; Manojkumar Sachidanandan; Riadh Badraoui; Mohd Adnan
Journal:  3 Biotech       Date:  2021-10-19       Impact factor: 2.406

4.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

Review 5.  Regulation of CD8+ T cell responses to infection with parasitic protozoa.

Authors:  Kimberly A Jordan; Christopher A Hunter
Journal:  Exp Parasitol       Date:  2010-05-21       Impact factor: 2.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.